GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst

Benzinga_recent_news12-19 23:36

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE:GSK). The collaboration aims to identify and develop...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592819645?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/19/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-19 23:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592819645","market":"hk","top_or_hot":-1,"title":"GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst","media":"Benzinga_recent_news","content":"<div>\n<p>CAMP4 Therapeutics Corporation (NASDAQ:CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE:GSK).\nThe collaboration aims to identify and develop...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49509978/gsk-deal-is-key-validation-for-camp4s-drug-discovery-platform-analyst\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-19 23:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49509978/gsk-deal-is-key-validation-for-camp4s-drug-discovery-platform-analyst><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CAMP4 Therapeutics Corporation (NASDAQ:CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE:GSK).\nThe collaboration aims to identify and develop...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49509978/gsk-deal-is-key-validation-for-camp4s-drug-discovery-platform-analyst\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4561","symbol_name":"索罗斯持仓","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49509978/gsk-deal-is-key-validation-for-camp4s-drug-discovery-platform-analyst","article_id":"2592819645","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/19/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49509978/gsk-deal-is-key-validation-for-camp4s-drug-discovery-platform-analyst","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592819645","pubTimestamp":1766158560,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4561":"索罗斯持仓","CAMP":"Camp4 Therapeutics Corp.","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BMRN":"拜玛林制药","GSK":"葛兰素史克","BK4532":"文艺复兴科技持仓","BK4020":"通信设备","BK4200":"专卖店","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4566":"资本集团","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","GSK.UK":"葛兰素史克","ASO":"Academy Sports & Outdoors, Inc.","BK4588":"碎股","BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"分析师：葛兰素史克交易是CAMP4药物发现平台的关键验证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAMP":1,"ASO":1,"BMRN":1,"GSK.UK":0.6,"GSK":1.5},"content_text":"CAMP4 Therapeutics Corporation (NASDAQ:CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE:GSK).\nThe collaboration aims to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.\nUnder the terms of the agreement, CAMP4 will receive a $17.5 million cash upfront payment.\nAlso Read: FDA Approves GSK’s Drug, Targets Severe Asthma With Two Doses Per Year\nAdditionally, CAMP4 has the potential to receive additional payments for certain development and commercial milestones, in addition to tiered royalties on future product sales.\nCAMP4 will utilize its proprietary RAP Platform to identify regRNAs controlling the expression of multiple gene targets and generate regRNA-targeting ASO candidates that amplify target gene expression for potential development.\nGSK will be responsible for the further development and commercialization of ASO drug candidates identified through the collaboration.\nIn October, CAMP4 Therapeutics initiated toxicology studies conducted for its lead product candidate, CMP-SYNGAP-01.\nThese studies will support the company’s planned submission of a clinical trial application, which could enable the initiation of a first-in-human Phase 1/2 trial in SYNGAP1-related disorders as early as the second half of 2026.\nWilliam Blair views the collaboration as another source of third-party RegRNA platform validation alongside the BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) collaboration in therapeutic areas outside the core focus of the company's wholly owned rare-disease franchise.\nWilliam Blair reiterates an Outperform rating on Camp.\n“We view investment from GSK as supportive of the notion that those results were confined to difficulties in data collection, separate from potential lack of platform activity, and we are particularly excited about the company's wholly owned CMP-002 set to enter the clinic in the second half of 2026 in SYNGAP-dEEs. We reiterate our Outperform rating on Camp4,” William Blair wrote on Thursday.\nPrice Action: CAMP stock is down 0.16% at $6.20 at the last check on Friday.\nRead Next:\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592819645","isCrawlerRequest":true}